Peer Review History

Original SubmissionDecember 30, 2023
Decision Letter - Gianmarco Ferrara, Editor

PONE-D-23-43149Tissue distribution of Coxiella burnetii and antibody responses in macropods co-grazing with livestock in Queensland, AustraliaPLOS ONE

Dear Dr. Tolpinrud,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Apr 04 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Gianmarco Ferrara, PhD, MVD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. 

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: 1. In this paper, the authors report results of a cross sectional survey of C. burnetii in macropods in Australia. Opportunistic sampling of 50 animals was done and different tissue samples were collected over a 3 day period.

2. The study seem to focus on i) diagnostics; comparing PCR detection frequencies from different sample types as well as suitability of three PCR markers for C. burnetii detection. The PCR results were also evaluated in comparison with serology results that were already reported somewhere else (ref 23). My criticism is that some of the principles of assay development/ optimisation were omitted. ii) The apparent sero detection as well as the molecular detection at animal level (referred to as apparent prevalence, with n=50 animals tested), including demographic data association. My criticism is that, the serology data seem to have been reported elsewhere and it is not clear why were these results included in this part of the study.

Reviewer #2: The manuscript "Tissue distribution of Coxiella burnetii and antibody responses in macropods co-grazing with livestock in Queensland, Australia" is well-written and describes the occurrence of Cb DNA in different organs/samples from kangaroos in Queensland. Moreover, blood samples were screened for antibodies.

I have only minor comments:

General comment: You talk about "prevalence" throughout the entire manuscript. In my opinion, you did not conduct a classical prevalence study. Your sample size follows a convenient sample approach. Therefore, I suggest using terms such as "detection rate" or "positivity rate" instead of "prevalence."

Line 66: "... promote transmission." Please insert a reference from the literature.

Line 120: Depending on the journal, but I suggest including the ethics statement at the end of the manuscript.

Lines 421-422: "... to occur more frequently than phase I." You cited very old literature. In recent years, newer findings have been published about the detection of Cb phase-specific antibodies in animals. Please revise the citations.

Table 1: Please include the English names of both kangaroo species.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Dr Nomakorinte Gcebe

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Reviewer #1:

Comment: “The study seem to focus on i) diagnostics; comparing PCR detection frequencies from different sample types as well as suitability of three PCR markers for C. burnetii detection. The PCR results were also evaluated in comparison with serology results that were already reported somewhere else (ref 23). My criticism is that some of the principles of assay development/ optimisation were omitted.”

Author response: Thank you for this comment. The IFA assay development and validation was previously published in detail in the below citation and is therefore only referenced in the current manuscript rather than repeated:

Tolpinrud A, Stenos J, Chaber AL, Devlin JM, Herbert C, Pas A, et al. Validation of an Indirect Immunofluorescence Assay and Commercial Q Fever Enzyme-Linked Immunosorbent Assay for Use in Macropods. J Clin Microbiol. 2022:e0023622. Epub 20220602. doi: 10.1128/jcm.00236-22

We have modified the text slightly (line 206-207) to make this clearer. Similarly, the PCR assays used here have been published previously (references 39-41) and are routinely used in the Australian Rickettsial Reference Laboratory for diagnostic and research purposes. They were therefore not developed or optimised as part of this study.

Comment: “The apparent sero detection as well as the molecular detection at animal level (referred to as apparent prevalence, with n=50 animals tested), including demographic data association. My criticism is that, the serology data seem to have been reported elsewhere and it is not clear why were these results included in this part of the study.”

Author response: Thank you for this comment. As mentioned in lines 112-117, only the overall seroprevalence rate (i.e. the crude apparent and estimated true seroprevalence) is reported elsewhere, while the current manuscript details the antibody distribution in relation to phases and demographics (age/sex/species). The referenced article (ref. no. 26) details the assay development and validation process, a by-product of which is the estimated seroprevalences for the tested kangaroo populations. A detailed breakdown of relative titres and phase variations, as is given in the current manuscript, is not included in the previous paper. Additionally, the current manuscript presents a unique opportunity to report on the serological results in the context of the molecular detection of C. burnetii, which was also not available in the cited article.

The reason this is highlighted in the text is to ensure transparency so readers are aware that the sample set detailed in this text is the same as the Roma population in reference 26.

Reviewer #2:

Comment: “General comment: You talk about "prevalence" throughout the entire manuscript. In my opinion, you did not conduct a classical prevalence study. Your sample size follows a convenient sample approach. Therefore, I suggest using terms such as "detection rate" or "positivity rate" instead of "prevalence."”

Author response: Thank you for this comment. It is our assessment that the kangaroos that were sampled were representative of the population of kangaroos at risk. For this reason, ‘prevalence’ is the appropriate term, acknowledging of course, that given a relatively small sample size the precision of our prevalence estimate(s) is not high. See lines 221 to 224 in the revised manuscript.

Comment: “Line 66: "... promote transmission." Please insert a reference from the literature.”

Author response: The manuscript has been updated with three relevant references (references 11-13).

Comment: “Line 120: Depending on the journal, but I suggest including the ethics statement at the end of the manuscript.”

Author response: Thank you for this comment. We followed the PLOS One author guidelines for the reporting of animal ethics, which state: “Manuscripts reporting animal research must state in the Methods section: The full name of the relevant ethics committee that approved the work, and the associated permit number(s). Where ethical approval is not required, the manuscript should include a clear statement of this and the reason why. Provide any relevant regulations under which the study is exempt from the requirement for approval.”

Comment: “Lines 421-422: "... to occur more frequently than phase I." You cited very old literature. In recent years, newer findings have been published about the detection of Cb phase-specific antibodies in animals. Please revise the citations.”

Author response: The references have been updated by removing the oldest citation and adding two more recent publications (references 63-68). We would welcome suggestions if the reviewer has any particular citations in mind.

Comment: “Table 1: Please include the English names of both kangaroo species.”

Author response: Thank you for this comment. The table has been updated as requested.

Attachments
Attachment
Submitted filename: response_to__reviewers.docx
Decision Letter - Gianmarco Ferrara, Editor

Tissue distribution of Coxiella burnetii and antibody responses in macropods co-grazing with livestock in Queensland, Australia

PONE-D-23-43149R1

Dear Dr. Tolpinrud,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Gianmarco Ferrara, PhD, MVD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: All comments have been addressed. The manuscript is ready for publication. No further modifications are necessary.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

**********

Formally Accepted
Acceptance Letter - Gianmarco Ferrara, Editor

PONE-D-23-43149R1

PLOS ONE

Dear Dr. Tolpinrud,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Gianmarco Ferrara

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .